Answers are grounded in this paper and cite their sources.
Background: Hydroxyurea is an antimetabolite medication used in the management of several hematological and oncological disorders, as well as sickle cell disease. Although generally well tolerated when prescribed and monitored appropriately, excessive exposure, dosing errors, impaired renal clearance, and prolonged treatment may result in clinically significant toxicity. Its major adverse effects include bone marrow suppression, gastrointestinal complications, mucocutaneous lesions, and, less frequently, neurological and pulmonary manifestations. Severe toxicity may lead to infection, bleeding, respiratory compromise, and other life-threatening complications. Aim: This review aims to examine the clinical features, underlying mechanisms, diagnostic evaluation, and management of hydroxyurea toxicity, with particular attention to emergency recognition and the contributions of nursing and respiratory care professionals. Methods: A narrative review approach was used to organize available clinical and pharmacological evidence concerning hydroxyurea toxicity. The review addresses its etiology, epidemiology, pathophysiology, toxicokinetics, clinical manifestations, diagnostic investigations, treatment strategies, differential diagnosis, and interprofessional management. Results: Hydroxyurea toxicity primarily results from inhibition of ribonucleotide reductase, leading to impaired DNA synthesis and suppression of rapidly dividing cells, particularly bone marrow precursors. Clinical manifestations include anemia, neutropenia, thrombocytopenia, gastrointestinal disturbances, oral mucositis, skin ulceration, and neurological abnormalities. Evaluation requires medication and exposure history, complete blood counts, renal function assessment, and symptom-directed investigations. Management is mainly supportive and may include fluid replacement, blood product transfusion, growth factor administration, infection management, and treatment of specific complications. Conclusion: Early recognition, appropriate monitoring, supportive treatment, and coordinated interprofessional care are essential to reducing complications and improving outcomes in patients with hydroxyurea toxicity.
No takes yet. Share an insight, caveat, or question.
Alhazmi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: